https://www.selleckchem.com/pr....oducts/ar-c155858.ht
ficacy. Functional validation by RNA or protein assay may add value for the accurate detection and interpretation of rare fusions.Here, we present an update of a phase 2 study of pembrolizumab in patients with advanced thymic carcinoma who failed previous therapies. Duration of response was approximately 3 years, and median survival was in excess of 2 years with a 5-year survival rate of 18%. The higher than expected incidence of severe autoimmune disorders (15%) did not substantially increase with a longer follow-up. Pembrolizumab i
Like
Comment
Share
